Portfolia
VC Fund
San Mateo, United States
Portfolia is a VC fund in San Mateo focused on Health Care and Biotechnology. Portfolia connects sophisticated investors and leaders with entrepreneurial companies. Their platform enables users to collaborate with other members and lead investors to evaluate innovative products and teams, join diligence teams, and immerse themselves in the investment process. It is an investment fund designed for women while backinginnovative companies for returns and impact.
- Total investments:
- 314
- Last investment:
- Lead investor:
- 6%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Portfolia invests in
Stages Portfolia invests in
Countries Portfolia invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 21 contacts → | |||
Round size
- Seed
- $1.2M–$4.3M
- Series A
- $347k–$15M
- Series B
- $5M–$51M
Investment Focus
Industry
- Health Care 37 (12%)
- Biotechnology 17 (5%)
- Software 16 (5%)
- Medical Device 13 (4%)
- Medical 12 (4%)
Stage
- Seed 55 (18%)
- Series A 35 (11%)
- Series B 14 (4%)
- Pre-Seed 7 (2%)
- Series C 7 (2%)
Country
- United States 103 (33%)
- Canada 1 (0%)
- Germany 1 (0%)
- Romania 1 (0%)
- Argentina 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Amber Caska
Investment Committee Member
|
Investment Committee Member | Total investments: 0 | Find email | |
Trish Costello
Founder & CEO
|
Founder & CEO | Total investments: 107 | Find email | |
Valentina Vitols
Limited Partner
|
Limited Partner | Total investments: 0 | Find email | |
|
Abbe Kligerman
Limited Partner
|
Limited Partner | Total investments: 0 | Find email | |
Bethann Kassman
Deal Lead
|
Deal Lead | Total investments: 14 | Find email | |
| See all 21 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Adjuvia Therapeutics
|
Adjuvia Therapeutics is a clinical-stage biopharmaceutical company pioneering blood-brain barrier (BBB)-penetrant nanoparticle therapies that address mitochondrial dysfunction, the fundamental biological mechanism driving rare and chronic degenerative diseases. | $8M / Seed / Jul 29, 2026 | |
Kind Designs
|
Kind Design uses 3D Printing technology to print living seawalls that mimic coral reefs and mangroves, hosting biodiversity and improving the quality of water. | $10M / Seed / Jul 16, 2026 | |
Osteoboost
|
Bone Health Technologies specializes in developing medical devices designed for low bone mass. Its solution is a gentle mechanical stimulation that mimics weight-bearing exercise, providing an effective non-drug intervention. It offers the OsteoBoost device that relies on safe, natural, and effective whole-body vibration technology usingvibrational energy to turn stem cells into the bone using the same mechanisms as physical exercise. The company was founded in 2018 and is headquartered in San Francisco, California. | $8M / Series A / Apr 09, 2026 | |
|
Osteoboost
|
Bone Health Technologies specializes in developing medical devices designed for low bone mass. Its solution is a gentle mechanical stimulation that mimics weight-bearing exercise, providing an effective non-drug intervention. It offers the OsteoBoost device that relies on safe, natural, and effective whole-body vibration technology usingvibrational energy to turn stem cells into the bone using the same mechanisms as physical exercise. The company was founded in 2018 and is headquartered in San Francisco, California. | $8M / Series A / Apr 09, 2026 | |
Nopalera
|
Nopalera creates Mexican botanical products such as moisturizers, soaps, cleansing creams, and other related products for baths and body that celebrate and elevate Latino culture. | $4M / Series A / Mar 24, 2026 | |
Trashie
|
Trashie provides a textile recycling service with rewards through its Take Back Bag and TrashieCash program. | $10M / Series A / Mar 17, 2026 | |
GrubMarket
|
GrubMarket develops a website where sellers can offer foods and other items at wholesale prices to customers. It offers products such as organic foods, vegetables, gluten-free foods, snacks, drinks, pantries, home goods, health and beauty products, baby and kids' products, pets, non-GMO foods, paleo foods, cholesterol-free, and no trans-fatfoods.GrubMarket also offers foods from local farms, fisheries, commercial kitchens, certified home kitchens, and restaurants. Mike Xu founded GrubMarket in 2014, with its headquarters in Newark in California with an additional office in San Francisco in California. | $50M / Series H / Feb 02, 2026 | |
The Cat Health Company
|
The Cat Health Company, which focuses on advancing feline longevity research to prevent or delay age-related illnesses in cats. | $1.2M / Seed / Oct 02, 2025 | |
Mercy BioAnalytics
|
Mercy BioAnalytics is a biotechnology company that aims to improve and save the lives of people through the early detection of cancer.It has developed a process that uses nano-particles that are extraordinarily abundant in blood and carry information about their parent cell – known as extracellular vesicles, or EVs – to detect stage I cancer.Paul Blavin and Joseph Sedlak founded the Natick, Massachusetts-based company in 2018. | $59M / Series B / Sep 03, 2025 | |
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $44M / Series C / Aug 12, 2025 | |
| See all 314 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Portfolia invest in?
Portfolia invests primarily in Health Care, Biotechnology and Software startups, most often at Seed and Series A stage. Most of the 314 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Portfolia's check size?
Portfolia typically joins rounds of $1.2M–$4.3M at Seed, $347k–$15M at Series A and $5M–$51M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Portfolia participates in.
How do I contact Portfolia?
Public channels for Portfolia include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Portfolia?
The team at Portfolia includes Amber Caska (Investment Committee Member), Trish Costello (Founder & CEO) and Valentina Vitols (Limited Partner), among 21 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
